hemagglutination inhibition

These two glycoproteins are the targets of numerous serologic reactions and tests including neutralization and hemagglutination inhibition.

The hemagglutination inhibition assay is a common variation of the HA assay used to measure flu-specific antibody levels in blood serum.

Without the GVI adjuvant, there is little or no detectable response when measuring hemagglutination inhibition (HI) antibodies.

However, its identity can be established by relatively stringent serologic tests such as virus neutralization (VN) and hemagglutination inhibition (HI).

The hemagglutination assay and its extension, the hemagglutination inhibition assay, were invented in 1941-42 by American virologist George Hirst.

The virus was negative by a hemagglutination inhibition assay using reference antisera against APMV-1 to APMV-10 (except APMV-5, which was not available).

He is particularly known for inventing the hemagglutination assay, a simple method for quantifying viruses, and adapting it into the hemagglutination inhibition assay, which measures virus-specific antibodies in serum.

But while Indian health workers did perform the standard blood test for Y. pestis, which sometimes can result in nonspecific reactions, they failed to perform another test, known as hemagglutination inhibition, that rules out the nonspecific reactions.

This hemagglutination inhibition assay (HIA) can be applied to many other viruses carrying a hemagglutinin molecule, including rubella, measles, mumps, parainfluenza, adenoviruses, polyomaviruses and arboviruses, and is still widely used in influenza surveillance and vaccine testing.

As of 2012, there are two BFDV tests available: A polymerase chain reaction (PCR) qualitative test which is very sensitive, and can detect the virus in extremely small quantities, and a quantitative (Hemagglutination Assay/Hemagglutination Inhibition) test.